Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model

Huang, D. B., Noviello, S. and Gemmell, C.G. (2019) Iclaprim reduces the incidence and severity of Staphylococcus aureus-induced septic arthritis in a murine model. Access Microbiology, 1(7), e000052. (doi: 10.1099/acmi.0.000052) (PMID:32974543) (PMCID:PMC7481738)

[img] Text
194172.pdf - Published Version
Available under License Creative Commons Attribution.

206kB

Abstract

Staphylococcus aureus is the most common non-gonococcal aetiology of septic arthritis. The efficacy of iclaprim against S. aureus LS-1, a clinical strain identified from a patient with septic arthritis, was studied in MF1 mice to evaluate the activity of iclaprim, which is in clinical development, in preventing joint infections. Iclaprim (2.5–80 mg kg− 1) administered as a single dose via the tail vein reduced the incidence of S. aureus septic arthritis and mortality in an experimental murine model of septic arthritis.

Item Type:Articles
Additional Information:Funding information: This study was sponsored by Motif BioSciences, Inc.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Gemmell, Professor Curtis
Authors: Huang, D. B., Noviello, S., and Gemmell, C.G.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Access Microbiology
Publisher:Microbiology Society
ISSN:2516-8290
ISSN (Online):2516-8290
Published Online:20 August 2019
Copyright Holders:Copyright © 2019 The Authors
First Published:First published in Access Microbiology 1(7): e000052
Publisher Policy:Reproduced under a Creative Commons license

University Staff: Request a correction | Enlighten Editors: Update this record